INTRODUCTION
The majority of failures following in vitro fertilization (IVF) occur after embryo transfer (ET). Apart from abnormal embryos, a nonreceptive endometrial environment may also be responsible for implantation failure (1) . Therefore, a marker for the prediction of endometrial receptivity would be of great use in deciding whether to proceed to ET or to cryopreserve the embryos. 1 First Department of Obstetrics and Gynecology, Semmelweis University, Faculty of Medicine, Budapest, Hungary. 2 "Fodor József" National Center of Public Health, "Frédéric Joliot-Curie" National Research Institute for Radiobiology and Radiohygiene, Budapest, Hungary. 3 To whom correspondence should be addressed; e-mail: humanic @noi1.sote.hu.
Assessment of endometrial receptivity can be based on histologic dating of the endometrium (2), evaluation of endometrial thickness and blood flow by transvaginal ultrasound (US) with color Doppler (3) (4) (5) , and on the measurement of uterine secretory proteins, including CA-125, which has been studied most extensively.
CA-125, an antigenic determinant of a glycoprotein expressed by most epithelial ovarian cancers, can also be measured in the peripheral circulation of healthy females (6) . However, contradictory data have been published on its exact source, whether endometrium or ovary. Studies on the value of CA-125 levels in the prediction of pregnancies, as measured at different time points of IVF treatment (5, (7) (8) (9) , have also yielded inconclusive data. Therefore, we examined whether serum CA-125 levels at oocyte pickup or on the first day of ovarian stimulation have any value in the prediction of treatment outcome and tried to infer consequences as to its source.
MATERIALS AND METHODS
Forty-two consecutive IVF patients with a clinical pregnancy (pregnant group) were matched with patients in whom treatment did not result in pregnancy (nonpregnant group) by age, type of infertility, serum estradiol (E 2 ) levels at ovulation induction, number of oocytes retrieved, and number of embryos replaced. Clinical pregnancy was detected if a fetal heartbeat was visible on US at 6-7 weeks of gestation. Twenty-eight additional consecutive pregnant patients without matched pairs were included to compare different pregnancy outcomes. Since CA-125 concentrations are known to be elevated in endometriosis (10) , no endometriosis patients were included.
Ovarian stimulation, ovulation induction, and oocyte pickup were carried out as described elsewhere (11) . Retrieved oocytes were fertilized with either IVF or ICSI technique. Up to four embryos were replaced 2 or 3 days later.
Venous blood samples were taken in the early follicular phase of a spontaneous cycle and assayed for serum FSH and E 2 . Estradiol was also measured in morning samples collected immediately before starting gonadotropin administration (day 1) and on the day of ovulation induction. CA-125 and inhibin B measurements were performed in serum samples collected on day 1 and on the day of oocyte pickup.
The description of FSH, E 2 , and inhibin B assays can be found elsewhere (12) . CA-125 concentrations were determined using an immunoradiometric kit ("Fodor József" National Center of Public Health, "Frédéric Joliot-Curie" National Research Institute for Radiobiology and Radiohygiene, Budapest, Hungary, in cooperation with CIS bio international, Gif-sur-Yvette, France) (detection limit, 0.5 U/mL, intra-and inter assay coefficients of variation, <4% and <5% over the range 0-750 U/mL).
Pregnancies were classified as early pregnancy loss [first-trimester abortions (n = 16) and ectopic pregnancies (n = 3)] and ongoing pregnancies, i.e., progression beyond 12 weeks' gestation [singleton (n = 27) and multiple deliveries (n = 21), and secondtrimester abortions (n = 3)]. No preclinical abortions were included.
McNemar's test, t-test for dependent or independent samples, Wilcoxon's matched pairs signed rank sum test, the Mann-Whitney U test, and Pearson's product-moment correlation analysis (r) was performed where appropriate. Power analysis showed that a 10 U/mL difference in CA-125 levels could be detected with nearly 100% power in our sample. All tests were two-tailed, with a confidence level of 95% (p < 0.05).
RESULTS
Baseline and stimulation characteristics were similar in pregnant and nonpregnant patients (Table I) . No significant difference was observed, as expected, in E 2 concentrations on the day of ovulation induction. Neither E 2 nor CA-125 or inhibin B before start of stimulation differed significantly between pregnant and nonpregnant subjects. No significant difference was observed in CA-125 or inhibin B, concentrations on the day of oocyte pickup either.
No statistically significant correlation was found between CA-125 levels and same-day E 2 or inhibin B concentrations, nor did CA-125 concentrations significantly correlate with E 2 levels at ovulation induction or the number of oocytes retrieved (data not shown). 
CA-125 to predict IVF treatment outcome
Within pregnant cycles, patients with early pregnancy loss (n = 19) had lower CA-125 levels on the day of oocyte retrieval (mean ± SD, 25.4 ± 18.7 U/mL) than patients with ongoing pregnancy (n = 51; 31.5 ± 19.9 U/mL) but this difference was just above the selected level of statistical significance (p = 0.044). Within the latter group, singleton (n = 29) and multiple ongoing pregnancies (n = 22) were compared and found to have similar serum concentrations of CA-125 at oocyte pickup (26.0 ± 14.6 vs. 37.6 ± 23.9 U/mL). No significant difference was observed between any pregnancy subgroups in CA-125 levels on day 1 of ovarian stimulation (data not shown).
In pregnant patients with serum samples available from both stimulation day 1 and day of oocyte pickup (n = 15), CA-125 levels were significantly lower at oocyte collection than on day 1 (p = 0.016) ( Table I and Fig. 1 ). No such difference was observed among nonpregnant patients (n = 14; p = 0.18).
DISCUSSION
Previous reports on the prognostic value of CA-125 in IVF cycles yielded contradictory results. Lanzone et al. found constant serum concentrations throughout stimulation and concluded that CA-125 was not useful in the prediction of treatment outcome (13) . In a study conducted by Miller et al., higher CA-125 levels were observed in pregnant than in nonpregnant cycles on the day before and, even more markedly, on the day of ovulation induction (7). Chryssikopoulos et al. found comparable serum concentrations on the day of ovulation induction but significantly higher values were observed at oocyte retrieval in the pregnant group (8) . This difference was lost, however, on the day of ET. Positive results were also reported by Tavmergen et al. (14) , whereas Brandenberger et al. demonstrated similar concentrations in conception and nonconception cycles for all sampling days mentioned above (15) . In a prospective study of 71 infertile women, substantial fluctuations were observed during ovarian suppression and stimulation as well as in the luteal phase, but these changes were independent of the outcome of IVF treatment (16) . In contrast with findings mentioned so far, Noci et al. found significantly lower CA-125 concentrations in pregnant than in nonpregnant patients at oocyte pickup (9) .
We observed no correlation between serum CA-125 and inhibin B concentrations measured in the same sample or with E 2 levels at ovulation induction or the number of oocytes retrieved, which argues against an ovarian source of serum CA-125 during stimulation (7, 14, 17) . A further counterargument is that CA-125 could not be detected immunohistochemically in theca or granulosa cells (6) , and no production could be demonstrated by human granulosa cells in culture (17) .
In earlier studies, no correlation with endometrial thickness or vascularization was observed (5,7), which argues against an endometrial source. However, a functional rather than quantitative change of the endometrium still may be at the origin of CA-125 changes (7) . Observations reported in the literature agree that CA-125 levels rise during the menstrual period as a consequence of endometrial disruption (18, 19) . This is probably due to an easier access of CA-125 from the endometrial epithelial lining into the circulation during menstruation (20) . Thus, endometrial shedding might directly be responsible for the rise of serum CA-125 levels. Noci et al. observed lower serum CA-125 concentrations at oocyte retrieval in pregnant than in nonpregnant cycles (9) and concluded that CA-125 might reflect the actual state of the endometrium and its tendency to shedding. In our study, no differences in CA-125 concentrations were observed between conception and nonconception cycles. Nevertheless, a decrease in serum levels by the time of oocyte pickup, as compared to the beginning of stimulation, was found in the pregnant group (Fig. 1A) , whereas the change was far less uniform in nonpregnant cycles and no significant difference was observed in the latter group (Fig. 1B) . Extending the idea of Noci et al. (9) , this decrease could also suggest a more compact endometrium, which might be more receptive to the implantation of the embryo.
In summary, our data suggest that measurement of serum CA-125 levels during stimulation is not predictive of subsequent pregnancy, even though a decrease from the start of stimulation to oocyte retrieval seemed to be associated with the establishment of pregnancy. Therefore, determination of CA-125 does not appear to be useful in predicting the outcome of IVF treatment.
